It is, therefore, plausible that selection of patients by tumor TIM‐3 level may be important for response, and that pancreatic cancers should be a focus for clinical trials of TIM‐3 antagonists.17, 20. This evidence concerns the gene HAVCR2 and pancreatic neoplasm.